Drug Discovery

Patient-Derived Xenografts – Review
Tech & Innovation Patient-Derived Xenografts – Review

In the battle against cancer, technological innovations have continually pushed the boundaries of what is possible in treatment and research. Among these breakthroughs, patient-derived xenograft (PDX) models have emerged as a transformative tool in precision oncology, an approach that tailors

How Do Key Proteins Enhance CAR-T Cell Therapy?
Research & Development How Do Key Proteins Enhance CAR-T Cell Therapy?

In the dynamic world of biopharmaceutical innovation, Ivan Kairatov stands out as an expert, particularly in the area of immunotherapy. With substantial experience in research and development, Ivan has been at the forefront of exploring the molecular intricacies of CAR-T cell therapy. This

How Will FDA's Fast-Track Vouchers Impact Drug Reviews?
Management & Regulatory How Will FDA's Fast-Track Vouchers Impact Drug Reviews?

Imagine a future where cutting-edge medications reach patients in record time. This future is not a distant dream but a tangible possibility thanks to the FDA's introduction of fast-track vouchers under the Commissioner’s National Priority Voucher program. In an era demanding swift responses to

Spatial Transcriptomics Tool – Review
Tech & Innovation Spatial Transcriptomics Tool – Review

In the quest to combat pervasive diseases, researchers have long grappled with understanding complex cellular environments that dictate disease progression. With innovations like Spatial Transcriptomics, profound insights have started unraveling the intricate tapestry of gene expression across

Can AI-Discovered Rentosertib Transform IPF Treatment?
Tech & Innovation Can AI-Discovered Rentosertib Transform IPF Treatment?

The arena of idiopathic pulmonary fibrosis (IPF) treatment is witnessing a revolutionary phase with the advent of AI-driven solutions. AI stands as a groundbreaking force in reimagining drug discovery and development processes, taking significant strides in IPF treatment. Rentosertib, discovered

How Will Moderna's mRESVIA Impact Younger Adults?
Management & Regulatory How Will Moderna's mRESVIA Impact Younger Adults?

As temperatures cool and the common cold season descends, a significant health risk may be lurking unnoticed for many younger adults. Respiratory Syncytial Virus (RSV), once considered a pediatric and elderly threat, has raised concerns for adults aged 18 to 59 with underlying health conditions.

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later